Dr. John Cush
@rheumnow.bsky.social
Know-it-Now. Info on RA, Stills disease, Lupus, Gout, Pregnancy, Spondylitis, Psoriasis, Drug Safety, Rheumatology Research, Medical Education & Drug Evaluation
Rheumnow.com
Rheumnow.com
SLE Prospect. Observational Study of 826 SLE pts over 3 yr for outcomes& IFN signature (IFNGS). 71% were IFNGS-high. IFNGS-high pts were younger. on GC w/ Hi SLEDAI-2K. SLEDAI-2K decreased over time, regardless of IFNGS. By 36mos, 45% had ≥1 flare; higher in IFNGS. academic.oup.com/rheumatology...
Disease progression in patients with systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS)
AbstractObjectives. We describe disease progression in patients from the SLE Prospective Observational Cohort Study (SPOCS; NCT03189875), investigating dif
academic.oup.com
November 15, 2025 at 12:01 AM
SLE Prospect. Observational Study of 826 SLE pts over 3 yr for outcomes& IFN signature (IFNGS). 71% were IFNGS-high. IFNGS-high pts were younger. on GC w/ Hi SLEDAI-2K. SLEDAI-2K decreased over time, regardless of IFNGS. By 36mos, 45% had ≥1 flare; higher in IFNGS. academic.oup.com/rheumatology...
IL-1 Inhibition in CPPD
Controlled clinical trials in patients with calcium Pyrophosphate Deposition Disease (CPPD) are scant. Now a metanalysis provides evidence that anakinra, an interleukin-1 inhibitor, is a promising alternative for patients with acute CPPD flares.
buff.ly/aHYVJnV
Controlled clinical trials in patients with calcium Pyrophosphate Deposition Disease (CPPD) are scant. Now a metanalysis provides evidence that anakinra, an interleukin-1 inhibitor, is a promising alternative for patients with acute CPPD flares.
buff.ly/aHYVJnV
November 14, 2025 at 10:01 PM
IL-1 Inhibition in CPPD
Controlled clinical trials in patients with calcium Pyrophosphate Deposition Disease (CPPD) are scant. Now a metanalysis provides evidence that anakinra, an interleukin-1 inhibitor, is a promising alternative for patients with acute CPPD flares.
buff.ly/aHYVJnV
Controlled clinical trials in patients with calcium Pyrophosphate Deposition Disease (CPPD) are scant. Now a metanalysis provides evidence that anakinra, an interleukin-1 inhibitor, is a promising alternative for patients with acute CPPD flares.
buff.ly/aHYVJnV
DAHLIAS study - Nipocalimab in Sjögren's Disease
Nipocalimab, a neonatal Fc receptor blocker that reduces circulating IgG and autoantibodies, was shown to be effective in a phase 2 trial in patients with severe Sjögren's disease.
rheumnow.com/news/dahlias...
Nipocalimab, a neonatal Fc receptor blocker that reduces circulating IgG and autoantibodies, was shown to be effective in a phase 2 trial in patients with severe Sjögren's disease.
rheumnow.com/news/dahlias...
November 14, 2025 at 8:01 PM
DAHLIAS study - Nipocalimab in Sjögren's Disease
Nipocalimab, a neonatal Fc receptor blocker that reduces circulating IgG and autoantibodies, was shown to be effective in a phase 2 trial in patients with severe Sjögren's disease.
rheumnow.com/news/dahlias...
Nipocalimab, a neonatal Fc receptor blocker that reduces circulating IgG and autoantibodies, was shown to be effective in a phase 2 trial in patients with severe Sjögren's disease.
rheumnow.com/news/dahlias...
Putting Steroid Tapering into Practice in SLE
Drs. Yuz Yusof and Ed Vital discuss abstract 1526 (Guidance For Corticosteroid Tapering In Patients With Systemic Lupus Erythematosus: Results From An International Delphi Consensus Project) presented at #ACR25.
buff.ly/sPKlog6
Drs. Yuz Yusof and Ed Vital discuss abstract 1526 (Guidance For Corticosteroid Tapering In Patients With Systemic Lupus Erythematosus: Results From An International Delphi Consensus Project) presented at #ACR25.
buff.ly/sPKlog6
November 14, 2025 at 7:02 PM
Putting Steroid Tapering into Practice in SLE
Drs. Yuz Yusof and Ed Vital discuss abstract 1526 (Guidance For Corticosteroid Tapering In Patients With Systemic Lupus Erythematosus: Results From An International Delphi Consensus Project) presented at #ACR25.
buff.ly/sPKlog6
Drs. Yuz Yusof and Ed Vital discuss abstract 1526 (Guidance For Corticosteroid Tapering In Patients With Systemic Lupus Erythematosus: Results From An International Delphi Consensus Project) presented at #ACR25.
buff.ly/sPKlog6
CAR-T Therapy: Where is it Heading?
Dr. Peter Nash summarizes several abstracts looking at CAR-T therapy from #ACR25.
rheumnow.com/video/car-t-...
Dr. Peter Nash summarizes several abstracts looking at CAR-T therapy from #ACR25.
rheumnow.com/video/car-t-...
November 14, 2025 at 5:03 PM
CAR-T Therapy: Where is it Heading?
Dr. Peter Nash summarizes several abstracts looking at CAR-T therapy from #ACR25.
rheumnow.com/video/car-t-...
Dr. Peter Nash summarizes several abstracts looking at CAR-T therapy from #ACR25.
rheumnow.com/video/car-t-...
Deep Learning Model Accurately Detects AS on MRI
Deep learning is moving from research to rheumatology clinics, revolutionizing the diagnosis of inflammatory diseases. AS is tricky to diagnose due to subtle early imaging and the need for expert radiologists.
buff.ly/2VM01Z1
Deep learning is moving from research to rheumatology clinics, revolutionizing the diagnosis of inflammatory diseases. AS is tricky to diagnose due to subtle early imaging and the need for expert radiologists.
buff.ly/2VM01Z1
November 14, 2025 at 4:01 PM
Deep Learning Model Accurately Detects AS on MRI
Deep learning is moving from research to rheumatology clinics, revolutionizing the diagnosis of inflammatory diseases. AS is tricky to diagnose due to subtle early imaging and the need for expert radiologists.
buff.ly/2VM01Z1
Deep learning is moving from research to rheumatology clinics, revolutionizing the diagnosis of inflammatory diseases. AS is tricky to diagnose due to subtle early imaging and the need for expert radiologists.
buff.ly/2VM01Z1
Western Australia study of 1854 SLE pts (40 yrs old). Interstitial lung disease was seen in in 3.8% of SLE, 26 fold more than controls. Risk factors for ILD included older age, smoking and serositis. SLE-ILD pts had higher mortality rates (MR 52.0, CI 37.0–71.1). academic.oup.com/rheumatology...
Interstitial lung disease in systemic lupus erythematosus: a 30-year population study
AbstractObjectives. To compare incidence, risk factors and outcomes for interstitial lung disease (ILD) between patients with systemic lupus erythematosus
academic.oup.com
November 14, 2025 at 3:02 PM
Western Australia study of 1854 SLE pts (40 yrs old). Interstitial lung disease was seen in in 3.8% of SLE, 26 fold more than controls. Risk factors for ILD included older age, smoking and serositis. SLE-ILD pts had higher mortality rates (MR 52.0, CI 37.0–71.1). academic.oup.com/rheumatology...
Sjögren's disease RCTs: Has the Long Drought Ended?
At #ACR25, two late breaking abstracts have triggered hope for patients suffering from Sjögren's disease.
rheumnow.com/news/sjogren...
At #ACR25, two late breaking abstracts have triggered hope for patients suffering from Sjögren's disease.
rheumnow.com/news/sjogren...
November 14, 2025 at 12:01 AM
Sjögren's disease RCTs: Has the Long Drought Ended?
At #ACR25, two late breaking abstracts have triggered hope for patients suffering from Sjögren's disease.
rheumnow.com/news/sjogren...
At #ACR25, two late breaking abstracts have triggered hope for patients suffering from Sjögren's disease.
rheumnow.com/news/sjogren...
PsA and Brain Fog
Dr. Akhil Sood reports on abstract 1421 (Impact of Psoriatic Arthritis Disease Activity and Fatigue on Subjective Cognitive Decline (“Brainfog”), presented at #ACR25.
rheumnow.com/video/psa-an...
Dr. Akhil Sood reports on abstract 1421 (Impact of Psoriatic Arthritis Disease Activity and Fatigue on Subjective Cognitive Decline (“Brainfog”), presented at #ACR25.
rheumnow.com/video/psa-an...
November 13, 2025 at 10:01 PM
PsA and Brain Fog
Dr. Akhil Sood reports on abstract 1421 (Impact of Psoriatic Arthritis Disease Activity and Fatigue on Subjective Cognitive Decline (“Brainfog”), presented at #ACR25.
rheumnow.com/video/psa-an...
Dr. Akhil Sood reports on abstract 1421 (Impact of Psoriatic Arthritis Disease Activity and Fatigue on Subjective Cognitive Decline (“Brainfog”), presented at #ACR25.
rheumnow.com/video/psa-an...
Robinson et al has published that Epstein-Barr virus infects and reprograms autoreactive B cells to drive the systemic autoimmune response in SLE www.science.org/doi/10.1126/...
Epstein-Barr virus reprograms autoreactive B cells as antigen-presenting cells in systemic lupus erythematosus
Epstein-Barr virus reprograms autoreactive B cells as antigen-presenting cells to promote pathogenic antinuclear T and B cell responses in lupus.
www.science.org
November 13, 2025 at 8:19 PM
Robinson et al has published that Epstein-Barr virus infects and reprograms autoreactive B cells to drive the systemic autoimmune response in SLE www.science.org/doi/10.1126/...
Mesothelin as a biomarker and potential therapeutic target in rheumatoid arthritis? Mesothelin is elevated in RA & animal models & promothes osteoclast differentiation & bony destruction. Blocking mesothelin has the potential to reduce bone destruction. www.cell.com/cell-reports...
Mesothelin as a biomarker and potential therapeutic target in rheumatoid arthritis bone destruction
Su et al. reveal that MSLN is significantly upregulated in RA patients and CIA animal models, where it drives osteoclast differentiation via the PI3K/AKT signaling. Inhibition of MSLN attenuates bone…
www.cell.com
November 13, 2025 at 8:14 PM
Mesothelin as a biomarker and potential therapeutic target in rheumatoid arthritis? Mesothelin is elevated in RA & animal models & promothes osteoclast differentiation & bony destruction. Blocking mesothelin has the potential to reduce bone destruction. www.cell.com/cell-reports...
November 13, 2025 at 8:01 PM
Learning just got smarter.
Every week, RheumIQ challenges you with a quick quiz on current rheumatology updates.
💡 Educational
🎯 Evidence-based
🧠 Addictive (in a good way)
Try it now and level up your clinical knowledge: rheumnow.com/game
Every week, RheumIQ challenges you with a quick quiz on current rheumatology updates.
💡 Educational
🎯 Evidence-based
🧠 Addictive (in a good way)
Try it now and level up your clinical knowledge: rheumnow.com/game
November 13, 2025 at 7:01 PM
Learning just got smarter.
Every week, RheumIQ challenges you with a quick quiz on current rheumatology updates.
💡 Educational
🎯 Evidence-based
🧠 Addictive (in a good way)
Try it now and level up your clinical knowledge: rheumnow.com/game
Every week, RheumIQ challenges you with a quick quiz on current rheumatology updates.
💡 Educational
🎯 Evidence-based
🧠 Addictive (in a good way)
Try it now and level up your clinical knowledge: rheumnow.com/game
Genetic Risks and Severe Cutaneous Reactions to Allopurinol
A cohort study shows a strong link between HLA-B*58:01 and HLA-A*34:02 alleles with allopurinol-induced SCARs. But, these alleles were absent in over 1/3 of cases, suggesting they are strong but incomplete risk indicators.
buff.ly/bWys22j
A cohort study shows a strong link between HLA-B*58:01 and HLA-A*34:02 alleles with allopurinol-induced SCARs. But, these alleles were absent in over 1/3 of cases, suggesting they are strong but incomplete risk indicators.
buff.ly/bWys22j
November 13, 2025 at 5:06 PM
Genetic Risks and Severe Cutaneous Reactions to Allopurinol
A cohort study shows a strong link between HLA-B*58:01 and HLA-A*34:02 alleles with allopurinol-induced SCARs. But, these alleles were absent in over 1/3 of cases, suggesting they are strong but incomplete risk indicators.
buff.ly/bWys22j
A cohort study shows a strong link between HLA-B*58:01 and HLA-A*34:02 alleles with allopurinol-induced SCARs. But, these alleles were absent in over 1/3 of cases, suggesting they are strong but incomplete risk indicators.
buff.ly/bWys22j
Swedish Registry study of adverse preg outcomes (APOs) after SSc Dx [n=941] or w/in 3 yrs [39] or > 3yrs pre-Dx [839]. SSc women have incr APOs post-Dx, preeclampsia (RR 3.8), preterm (3.3), C-section (2.5); but also incr APO risk w/in 3 yrs of Dx acrjournals.onlinelibrary.wiley.com/doi/10.1002/...
acrjournals.onlinelibrary.wiley.com
November 13, 2025 at 4:06 PM
Swedish Registry study of adverse preg outcomes (APOs) after SSc Dx [n=941] or w/in 3 yrs [39] or > 3yrs pre-Dx [839]. SSc women have incr APOs post-Dx, preeclampsia (RR 3.8), preterm (3.3), C-section (2.5); but also incr APO risk w/in 3 yrs of Dx acrjournals.onlinelibrary.wiley.com/doi/10.1002/...
NHANES study of 4,622 adults, including 296 w/ RA, shows volatile organic compounds (VOCs) & metabolites (mVOCs) exposures increases the risk of #RA (OR: 1.23 - 1.37), especially in females. www.frontiersin.org/journals/pub...
Frontiers | Association between volatile organic compound co-exposure and the prevalence of rheumatoid arthritis: a nationwide cross-sectional study
BackgroundEnvironmental contaminants, especially volatile organic compounds (VOCs) and their metabolites (mVOCs), are of significant interest for treating au...
www.frontiersin.org
November 13, 2025 at 3:04 PM
NHANES study of 4,622 adults, including 296 w/ RA, shows volatile organic compounds (VOCs) & metabolites (mVOCs) exposures increases the risk of #RA (OR: 1.23 - 1.37), especially in females. www.frontiersin.org/journals/pub...
#ACR25 PsA Topic Panel
A focused conversation on the latest in psoriatic arthritis care - from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping PsA practice right now.
buff.ly/CxyT6b2
A focused conversation on the latest in psoriatic arthritis care - from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping PsA practice right now.
buff.ly/CxyT6b2
November 13, 2025 at 12:01 AM
#ACR25 PsA Topic Panel
A focused conversation on the latest in psoriatic arthritis care - from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping PsA practice right now.
buff.ly/CxyT6b2
A focused conversation on the latest in psoriatic arthritis care - from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping PsA practice right now.
buff.ly/CxyT6b2
New Approaches to Therapy in PsA
Dr. Arthur Kavanaugh offers an overview of new approaches to therapy in psoriatic arthritis, at #ACR25.
rheumnow.com/video/new-ap...
Dr. Arthur Kavanaugh offers an overview of new approaches to therapy in psoriatic arthritis, at #ACR25.
rheumnow.com/video/new-ap...
November 12, 2025 at 10:01 PM
New Approaches to Therapy in PsA
Dr. Arthur Kavanaugh offers an overview of new approaches to therapy in psoriatic arthritis, at #ACR25.
rheumnow.com/video/new-ap...
Dr. Arthur Kavanaugh offers an overview of new approaches to therapy in psoriatic arthritis, at #ACR25.
rheumnow.com/video/new-ap...
Biologic use in 5008 IBD pts finds higher infxn (SIE) rates (vs RA, PsO). In UC SIE rate was 5.5/100PY w/ vedolizumab & 7/100PY w/ other biologics. In Crohns SIE rate was 7.9/100PY w/ vedolizumab & 6.5/100PY w/other biologics (adj HR 1.15; 0.95–1.40) (P .16) www.sciencedirect.com/science/arti...
www.sciencedirect.com
November 12, 2025 at 9:57 PM
Biologic use in 5008 IBD pts finds higher infxn (SIE) rates (vs RA, PsO). In UC SIE rate was 5.5/100PY w/ vedolizumab & 7/100PY w/ other biologics. In Crohns SIE rate was 7.9/100PY w/ vedolizumab & 6.5/100PY w/other biologics (adj HR 1.15; 0.95–1.40) (P .16) www.sciencedirect.com/science/arti...
#ACR25 Rheumatology Round Up
Drs. Jack Cush & Arthur Kavanaugh, two of rheumatology’s most trusted voices, provide a breakdown of the latest breakthroughs and hottest topics in rheumatology from #ACR25.
rheumnow.com/news/acr-202...
Drs. Jack Cush & Arthur Kavanaugh, two of rheumatology’s most trusted voices, provide a breakdown of the latest breakthroughs and hottest topics in rheumatology from #ACR25.
rheumnow.com/news/acr-202...
November 12, 2025 at 8:01 PM
#ACR25 Rheumatology Round Up
Drs. Jack Cush & Arthur Kavanaugh, two of rheumatology’s most trusted voices, provide a breakdown of the latest breakthroughs and hottest topics in rheumatology from #ACR25.
rheumnow.com/news/acr-202...
Drs. Jack Cush & Arthur Kavanaugh, two of rheumatology’s most trusted voices, provide a breakdown of the latest breakthroughs and hottest topics in rheumatology from #ACR25.
rheumnow.com/news/acr-202...
#ACR25 Best Abstracts - Day 4
Here's the last installment of our "ACR Best" abstracts as chosen by the RheumNow faculty. Most of these were from the final day, specifically day 4, but a few were noteworthy holdovers from day 3. Enjoy!
rheumnow.com/news/acr25-b...
Here's the last installment of our "ACR Best" abstracts as chosen by the RheumNow faculty. Most of these were from the final day, specifically day 4, but a few were noteworthy holdovers from day 3. Enjoy!
rheumnow.com/news/acr25-b...
November 12, 2025 at 7:02 PM
#ACR25 Best Abstracts - Day 4
Here's the last installment of our "ACR Best" abstracts as chosen by the RheumNow faculty. Most of these were from the final day, specifically day 4, but a few were noteworthy holdovers from day 3. Enjoy!
rheumnow.com/news/acr25-b...
Here's the last installment of our "ACR Best" abstracts as chosen by the RheumNow faculty. Most of these were from the final day, specifically day 4, but a few were noteworthy holdovers from day 3. Enjoy!
rheumnow.com/news/acr25-b...
November 12, 2025 at 5:03 PM
The Interview (11.7.2025)
I've conducted thousands of interviews. I'm seeking the "right one," while applicants are both nervous and hopeful. My extensive experience has shaped my views on interviewing, which have evolved in the digital age.
buff.ly/pUdeNm3
I've conducted thousands of interviews. I'm seeking the "right one," while applicants are both nervous and hopeful. My extensive experience has shaped my views on interviewing, which have evolved in the digital age.
buff.ly/pUdeNm3
November 12, 2025 at 4:00 PM
The Interview (11.7.2025)
I've conducted thousands of interviews. I'm seeking the "right one," while applicants are both nervous and hopeful. My extensive experience has shaped my views on interviewing, which have evolved in the digital age.
buff.ly/pUdeNm3
I've conducted thousands of interviews. I'm seeking the "right one," while applicants are both nervous and hopeful. My extensive experience has shaped my views on interviewing, which have evolved in the digital age.
buff.ly/pUdeNm3
November 12, 2025 at 3:03 PM
Diagnostic Delays in PsA: A Radiographic Perspective
Dr. Brian Jaros reports on abstract 1713 (Diagnostic Delay in Psoriatic Arthritis and its Impact on Radiological Outcomes: A Systematic Review and Meta-analysis of 23,894 Patients), presented at #ACR25.
rheumnow.com/video/diagno...
Dr. Brian Jaros reports on abstract 1713 (Diagnostic Delay in Psoriatic Arthritis and its Impact on Radiological Outcomes: A Systematic Review and Meta-analysis of 23,894 Patients), presented at #ACR25.
rheumnow.com/video/diagno...
November 12, 2025 at 12:00 AM
Diagnostic Delays in PsA: A Radiographic Perspective
Dr. Brian Jaros reports on abstract 1713 (Diagnostic Delay in Psoriatic Arthritis and its Impact on Radiological Outcomes: A Systematic Review and Meta-analysis of 23,894 Patients), presented at #ACR25.
rheumnow.com/video/diagno...
Dr. Brian Jaros reports on abstract 1713 (Diagnostic Delay in Psoriatic Arthritis and its Impact on Radiological Outcomes: A Systematic Review and Meta-analysis of 23,894 Patients), presented at #ACR25.
rheumnow.com/video/diagno...